Allergy & Immunology Financial Clearance Software

Financial Clearance in a Allergy & Immunology Practice

Clearance in allergy covers three kinds of care, each with its own rules. Skin and blood tests are checked against the plan's allergy testing benefit, which some payers return as its own line in the 271 reply. Shots are checked for the copay per visit, since a patient in build-up may come in each week. Biologics take the most work. Staff first decide if the drug is given in the office, under the medical benefit, or at home, under the drug benefit. Then they send the prior auth with the facts the payer asks for, such as blood eosinophil counts, asthma control and current inhalers. Allergy & immunology financial clearance software tracks each request and its dates. It holds the shot visit until the approval is on file and checks insured patients for maker copay programs. Last, the patient gets an estimate for the test, the shot or the drug.

Why Is Financial Clearance Different in Allergy & Immunology?

Allergy services look small one at a time, but they add up. A testing visit can carry dozens of test units. A shot patient may owe a copay at each visit for a long stretch. Patients who don't hear about these costs early tend to stop, and allergy shots only work when the course is finished.

Biologics are where the money is at risk. Drugs such as omalizumab, mepolizumab, benralizumab and tezepelumab cost a great deal per dose. Payers want prior auth with clinical proof, and many send self-injected doses to the drug benefit. A dose given in the office without approval on the right benefit is often a loss the practice can't get back.

Medicare adds its own limits. Some Medicare contractors cap test counts. One contractor's shot policy says allergy drops under the tongue are not reasonable and necessary. An Advance Beneficiary Notice may be needed before a service like that. Financial clearance in allergy has to know each payer's rules before the visit, not after the denial.

What Allergy & Immunology Financial Clearance Software Handles

Testing service type (STC 79)

X12 lists service type code 79 for allergy testing. When a payer answers that code in its 271 reply, staff see the testing benefit itself. The 270 check goes out when the visit is booked. (X12 Service Type Codes (used in 270/271 eligibility transactions))

Biologic approval criteria

UnitedHealthcare's commercial policy for Nucala and Fasenra asks for severe asthma and a blood eosinophil count of at least 150 cells per microliter. The drug must be used with inhaled controller medicine, and a lung or allergy specialist must prescribe it. Where the payer takes it, the request goes out as an X12 278. (UnitedHealthcare Commercial Medical Benefit Drug Policy 2026D0055AA: Respiratory Interleukin-5 Inhibitor)

Site of care review

UnitedHealthcare's site-of-care policy reviews doses of drugs such as Xolair, Nucala, Fasenra and Tezspire given in a hospital outpatient clinic. For a hospital-based allergy clinic, the setting is cleared along with the drug. (UnitedHealthcare Commercial Medical Benefit Drug Policy 2026D0121V: Provider Administered Drugs, Site of Care)

Self-given doses (Medicare)

Medicare Part B does not cover omalizumab when patients give it to themselves. Clearance confirms that a Medicare patient's doses will be given in the office before the drug is billed to Part B. (CMS Medicare Coverage Database, Billing and Coding Article A52448: Omalizumab)

Test count limits (Medicare)

Palmetto's allergy testing LCD says more than 70 skin prick tests and 40 intradermal tests for an inhalant workup are not reasonable and necessary. For Medicare patients in its states, the planned count is checked against that limit first. (CMS Medicare Coverage Database, LCD L40328: Allergy Diagnostic Testing (Palmetto GBA, effective 2026-09-27))

Allergy drops (Medicare)

CGS's shot policy lists sublingual immunotherapy as not reasonable and necessary. When a Medicare patient in its states wants allergy drops, staff explain the cost and give an ABN before the service. (CMS Medicare Coverage Database, LCD L40056: Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT) (CGS))

Maker copay programs

Insured patients starting a biologic are checked for the maker's copay program before the first dose. OIG has warned that maker copay coupons raise kickback concerns when federal programs pay for the drug. So Medicare patients are pointed to other help, such as charity funds. (HHS-OIG Special Advisory Bulletin: Pharmaceutical Manufacturer Copayment Coupons (2014))

How Does Allergy & Immunology Financial Clearance Software Work?

1. 1. Check coverage at booking

   A 270 check runs when the visit is booked. The 271 reply shows copays, deductibles and the testing benefit where the payer returns it, so plan changes are caught early.

2. 2. Sort the drug benefit

   For each biologic, staff note whether it is given in the office under the medical benefit or at home under the drug benefit. That choice decides where the request goes.

3. 3. Send and track the request

   The request goes out with eosinophil counts, control scores and inhaler history from the record. Approval numbers, dates and dose counts are saved, and allergy patient scheduling holds the shot visit until approval is on file.

4. 4. Look for financial help

   Insured patients are checked for maker copay programs, and others for charity help. Credits are noted, so the patient's balance is right from the start.

5. 5. Give the estimate

   The patient gets an estimate for the test, the shot copay or the drug before the service. Uninsured patients get a good faith estimate, and later balances go out through allergy invoicing.

Allergy & Immunology Financial Clearance Software vs. Generic Software

Who Uses It in a Allergy & Immunology Practice

• Financial counselor: One queue of open biologic requests with the clinical facts attached, and copay program checks in the same place.
• Front desk: Copays and testing benefits ready at booking, so shot patients know what each visit costs.
• Practice owner: Fewer write-offs on costly drugs, since biologics are given only with approval on the right benefit, and fewer approval denials to work later.